How a Drug Actually Gets Made

2026-04-16 · Source: No Priors: AI, Machine Learning, Tech, & Startups · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Health & Medical Research · Depth: Novice, quick

Summary

The process of developing a new medicine is a complex, multi-stage endeavor spanning 7 to 10 years, beginning with identifying a biological target and designing a drug molecule. This involves extensive testing in vitro and in vivo, followed by progressively larger human clinical trials. Concurrently, pharmaceutical companies must establish scalable, safe, and quality-controlled manufacturing processes while navigating stringent regulatory approvals. Benchling specializes in managing the vast, heterogeneous scientific data generated throughout this entire laboratory phase, organizing it to be searchable and actionable for scientists making critical development decisions.

Key takeaway

For research scientists and R&D managers overseeing drug development, understanding the full scope of the 7-10 year process, from target identification to commercialization, is critical. You should prioritize robust data management solutions like Benchling to consolidate and organize the heterogeneous scientific data, ensuring efficient decision-making and regulatory navigation throughout the complex pipeline.

Key insights

Drug development is a decade-long, data-intensive process requiring integrated data management for scientific decision-making.

Principles

• Integrated data is crucial for drug development.
• Regulatory navigation is continuous.
• Scalable manufacturing is essential.

Method

Benchling's approach involves centralizing, organizing, and making searchable all scientific data from drug discovery labs, enabling scientists to make informed decisions throughout the complex development pipeline.

In practice

• Centralize all lab data.
• Ensure data is searchable.
• Streamline regulatory compliance.

Topics

• Drug Discovery
• Drug Development Process
• Clinical Trials
• Regulatory Navigation
• Scientific Data Management

Best for: Research Scientist, Domain Expert

Related on AIssential

• Is AI Drug Discovery Becoming a Data Infrastructure Race? — AI drug discovery's primary bottleneck is the availability of diverse, relevant biological training data, not model architecture or compute.
• FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder — Navigating highly regulated sectors like healthcare demands rigor, early regulatory engagement, and a resilient company culture.
• SMDD-Bench: Can LLMs Solve Real-World Small Molecule Drug Design Tasks? — SMDD-Bench reveals current LLMs solve only 40.2% of complex drug design tasks, underscoring significant challenges in autonomous scientific discovery.
• The Future Of Drug Discovery Is 4 Billion Years Old (Viswa Colluru, Founder & CEO at Enveda) — AI-driven exploration of nature's chemistry offers a potent, overlooked pathway for discovering first-in-class, affordable medicines.
• AI Improving Dose Decisions and Patient Outcomes in Oncology- with Shefali Kakar of Novartis — AI-driven data integration refines oncology dose decisions, safety, and patient variability, accelerating drug development.
• He Raised $70M to Cure Every Disease With AI — AI agents, particularly specialized models, significantly accelerate scientific discovery by removing human talent bottlenecks and enabling high-throughput reasoning.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by No Priors: AI, Machine Learning, Tech, & Startups.